AtriCure, Inc. (NASDAQ:ATRC) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Atricure Inc. (ATRC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hood River Capital Management David Swank | 2,923,731 | $89,349,219 | 1.31% | |
| 2. | DAFNA Capital Management Nathan Fischel | 641,673 | $19,609,527 | 4.98% | |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 639,400 | $19,540,064 | -4% | 0.04% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 619,166 | $18,921,713 | +38% | 0.02% |
| 5. | Millennium Management Israel Englander | 347,836 | $10,629,868 | -2% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.25 | 5,000 | Officer | 103,290 | 2024-05-30 | Filing | |
| $76.68 | 34 | Director | 16,228 | 2021-04-30 | Filing | |
| $40.54 | 12,350 | Director | 41,036 | 2020-11-17 | Filing | |
| $24.86 | 500 | Director | 25,670 | 2019-09-12 | Filing | |
| $17.64 | 11,000 | Director | 16,805 | 2018-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.07 | 3,500 | Director | 8,970 | 2024-08-15 | Filing | |
| $24.09 | 1,500 | Officer | 71,284 | 2024-05-01 | Filing | |
| $30.39 | 1,500 | Officer | 72,784 | 2024-04-01 | Filing | |
| $32.16 | 1,885 | Officer | 50,954 | 2024-03-18 | Filing | |
| $36.72 | 1,500 | Officer | 74,284 | 2024-03-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,653,205 | $142,201,945 | 0% | |
| 2. | 4,311,265 | $131,752,250 | 0% | |
| 3. | 3,835,449 | $117,211,321 | 0.03% | |
| 4. | 2,528,614 | $77,274,444 | 0.48% | |
| 5. | 2,375,233 | $72,587,000 | 0.08% |
News See All
Why These 15 Stocks Are Skyrocketing in 2025
The market has started to favor smaller companies in 2025, and stocks between $1 billion and $5 billion in market value are attracting renewed interest.
AtriCure, Inc. (NASDAQ:ATRC) Q3 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Here’s Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2024 investor letter.
AtriCure, Inc. (NASDAQ:ATRC) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure (ATRC) Stock Slipped on Competition Threat
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter.
AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to AtriCure’s First Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
AtriCure (ATRC) Fell on Competitor Action
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call Transcript
AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.22. AtriCure, Inc.
Billionaire Hedge Funds
